12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VS-6063: Phase I/Ib started

Verastem began an open-label, dose-escalation, U.S. Phase I/Ib trial to evaluate twice-daily oral VS-6063 plus IV paclitaxel given on days 1, 8 and 15 of a 28-day cycle in...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >